Translating the DARPin® difference into patient benefit.
At Molecular Partners we are focused singly on one task: translating the differentiating features of DARPin® proteins into patient benefit. We constantly challenge current approaches to come up with solutions to move the needle of medicine.
Some targets, such as peptide-MHC complexes, carry high therapeutic promise, but have proven exceptionally challenging with conventional approaches.
DARPin® proteins bind their targets with a concave surface that might be ideally suited to engage with pMHC complexes with high affinity and specificity.
Example: pMHC-DARPin® candidates
Activating immune cells is a powerful way to fight cancer. Systemic activation of immune cells can however lead to dose-limiting side effects, providing no therapeutic window, as is often seen for agonistic immune cell targets.
Current approaches targeting Her-2 use either immune cells or deliver drugs to kill tumor cells, both of which can carry side effects.
Allosteric modulation of Her-2 can “handcuff” the protein and kill tumor cells without the need of the immune system or drug delivery.
Under treatment with standard therapies some tumors react by upregulating escape pathways, leading to adaptive resistance.
Multi-DARPin® approaches are ideally suited to block different escape pathways in parallel, with the potential to overcome resistance and reactivate standard of care therapies.